J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

Johnson & Johnson unveiled first-in-human Phase 1 data for pasritamig (JNJ-78278343), a first-in-class bispecific antibody targeting KLK2, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Pasritamig is designed to engage T-cells and direct the immune system against prostate cancer cells, specifically in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed despite multiple lines of prior therapy.

Early results from the study show promising anti-tumor activity and low rates of treatment-related adverse events, supporting KLK2’s potential as a highly specific and novel target for advanced prostate cancer.

The phase 1 data demonstrate pasritamig was well tolerated and safe in the outpatient setting, making it a candidate for broader community use.

J&J remains the sole major developer of KLK2-targeted bispecifics, emphasizing both the breadth and the solitary nature of this therapeutic approach in prostate cancer research.54

Sources:

4. https://www.investor.jnj.com/files/doc_news/2025/Jun/01/FINAL-Pasritamig-Data-Release-ASCO-2025-1.pdf

5. https://www.jnj.com/media-center/press-releases/johnson-johnson-unveils-first-in-human-results-for-pasritamig-showing-early-anti-tumor-activity-in-prostate-cancer